Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety

Journal of Pharmaceutical Health Services Research

Volumn 3, Issue 1, 2012, Pages 41-47

  Jones, Christopher A ^a   Rojavin, Mikhail ^a   Baggish, Jeffrey S ^a  

^a CSL BEHRING   (United States)

Author keywords

HRQoL; Immunoglobulin G; PID; SCIG

Indexed keywords

HUMAN IMMUNOGLOBULIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ETHNICITY; FEMALE; HUMAN; IMMUNE DEFICIENCY; MALE; MENTAL HEALTH; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; PRIMARY IMMUNODEFICIENCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE;

EID: 84857066175     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/j.1759-8893.2011.00076.x     Document Type: Article

References (24)

1. Blaese R etal., ed. Patient and Family Handbook for Primary Immunodeficiency Diseases, 4th edn. Towson, MD: Immune Deficiency Foundation, 2007.
2. National Institute of Allergy and Infectious Disease. Primary Immune Deficiency Diseases: Quick Facts (2009). 2011. (accessed 1 April 2011).
3. Cooper MA etal. Primary immunodeficiencies. Am Fam Physician 2003; 68: 2001-2008.
4. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004; 112: 1-7.
5. Weiler CR. Immunoglobulin therapy: history, indications, and routes of administration. Int J Dermatol 2004; 43: 163-166.
6. Gardulf A etal. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs 1995; 21: 917-927.
7. Gardulf A etal. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114: 936-942.
8. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006; 6: 434-442.
9. Gardulf A etal. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008; 126: 81-88.
10. Nicolay U etal. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006; 26: 65-72.
11. Müller-Nordhorn J etal. Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease.Heart 2004; 90: 523-527.
12. Nicolay U etal. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res 2005; 14: 1683-1691.
13. Atkinson MJ etal. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
14. Atkinson MJ etal. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005; 8(Suppl. 1): S9-S24.
15. Shaw JW etal. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43: 203-220.
16. Ware JE etal. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, 1993.
17. Angst F etal. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001; 45: 384-391.
18. Ehrich EW etal. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000; 27: 2635-2641.
19. Khanna D, Tsevat J. Health-related quality of life - an introduction. Am J Manag Care 2007; 13(Suppl. 9): S218-S223.
20. Kosinski M etal. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478-1487.
21. Norman GR etal. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-592.
22. Thumboo J etal. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999; 26: 97-102.
23. Wells GA etal. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 557-560.
24. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005; 14: 1523-1532.